glepaglutide
Peptideexperimental
Clinical trial activity
11 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
7
Phase 3
6
Phase 4
0
Earliest trial started Jan 1, 2009 (NCT00868660)
Timeline
Indications
Mechanism of action
GLP2R agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297761 ↗
Also known as
- zp1848
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07228403 | Phase 3 | Nov 25, 2025 | Zealand Pharma |
| NCT07197944 | Phase 3 | Oct 23, 2025 | Zealand Pharma |
| NCT04991311 | Phase 3 | Aug 10, 2021 | Zealand Pharma |
| NCT04881825 | Phase 3 | Jun 16, 2021 | Zealand Pharma |
| NCT04318743 | Phase 1 | Mar 4, 2020 | Zealand Pharma |
| NCT04178447 | Phase 1 | Dec 31, 2019 | Zealand Pharma |
| NCT03905707 | Phase 3 | May 7, 2019 | Zealand Pharma |
| NCT03690206 | Phase 3 | Sep 25, 2018 | Zealand Pharma |
| NCT03279302 | Phase 1 | Sep 4, 2017 | Zealand Pharma |
| NCT02690025 | Phase 2 | Feb 1, 2016 | Larix A/S, Zealand Pharma |
| NCT00868660 | Phase 1 | Jan 1, 2009 | Zealand Pharma |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zealand Pharma | For profit | 11 | 11 | 3 | 2009 |
| Larix A/S | For profit | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1